Skip to main content
SpringerLink
Log in

Multiple Myeloma and the Kidney

  • Chapter
  • First Online:
Clinical Decisions in Nephrology, Hypertension and Kidney Transplantation

Abstract

RG, a 60-year-old African-American man, presents to your clinic with a 6-week history of fatigue and right hip pain, which he attributes to a fall a few months ago. He has not seen a physician in years because he has felt well. However, he did visit the ER a week ago for his hip pain and labs showed a creatinine of 1.9 mg/dL. He has been taking 800–1,200 mg of ibuprofen daily for the last 2 weeks. His physical examination is notable for pain over the right hip. Laboratory studies show a creatinine of 4.6 mg/dL, calcium of 11 mg/dL, and hemoglobin of 7.2 g/dL. Plain films of the right hip show osteolytic lesions. Urine dipstick is negative for protein.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kyle RA. Multiple myeloma: an odyssey of discovery. Br J Haematol. 2000;111:1035–44.

    Article  PubMed  CAS  Google Scholar 

  2. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962–72.

    Article  PubMed  CAS  Google Scholar 

  3. Clamp JR. Some aspects of the first recorded case of multiple myeloma. Lancet. 1967;290:1354–6.

    Article  Google Scholar 

  4. Korngold L, Lipari R. Multiple-myeloma III. The antigenic relationship of BenceJones proteins to normal gammaglobulin and multiple-myeloma serum proteins. Cancer. 1956;9:262–72.

    Article  PubMed  CAS  Google Scholar 

  5. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–57.

    Article  Google Scholar 

  6. Herrara G. Renal lesions associated with plasma cell dyscrasias, practical approach to diagnosis, new concepts and challenges. Arch Pathol Lab Med. 2009;133:240–67.

    Google Scholar 

  7. Korbet SM, Schwartz MM. Multiple myeloma. J Am Soc Nephrol. 2006;17:2533–45.

    Article  PubMed  Google Scholar 

  8. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860–73.

    Article  PubMed  CAS  Google Scholar 

  9. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.

    Article  PubMed  Google Scholar 

  10. Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol. 2001;12:1482–92.

    PubMed  CAS  Google Scholar 

  11. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412.

    Article  PubMed  Google Scholar 

  12. Kyle RA, Therneau TM, Rajkumar SV. Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. Cancer. 2004;101:2667–74.

    Article  PubMed  Google Scholar 

  13. US Renal Data System: USRDS 2005 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute Diabetes and Digestive and Kidney Diseases; 2005.

    Google Scholar 

  14. Dimopoulos MA, Terpos E, Chanan-Khan A. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncol. 2010;29:4976–84.

    Article  Google Scholar 

  15. Christensen EI, Brin H. Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol. 2001;280:F562–73.

    PubMed  CAS  Google Scholar 

  16. Batuman V. Proximal tubular injury in myeloma. In: Herrera GA, editor. The kidney in plasma cell dyscrasias, Contribution to nephrology, vol. 153. Basel: Karger; 2007. p. 87–104.

    Chapter  Google Scholar 

  17. Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Engl J Med. 1991;324:1845–51.

    Article  PubMed  CAS  Google Scholar 

  18. Monteseny JJ, Kleinknecht D, Meyrier A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant. 1998;13:1438–45.

    Article  Google Scholar 

  19. Basnayake K, Ying WZ, Wang PX, et al. Immunoglobulin light chains activate tubular epithelial cells through redox signaling. J Am Soc Nephrol. 2010;21:1165–73.

    Article  PubMed  CAS  Google Scholar 

  20. Merlini G, Pozzi C. Mechanisms of renal damage in plasma cell dyscrasias: an overview. In: Herrera GA, editor. The kidney in plasma cell dyscrasias, Contribution to nephrology, vol. 153. Basel: Karger; 2007. p. 66–86.

    Chapter  Google Scholar 

  21. Keeling J, Herrera GA. The mesangium as a target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage. In: Herrera GA, editor. The kidney in plasma cell dyscrasias, Contribution to nephrology, vol. 153. Basel: Karger; 2007. p. 116–34.

    Chapter  Google Scholar 

  22. Ronco P, Plaisier E, Mougenot B. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol. 2006;1:1342–50.

    Article  PubMed  CAS  Google Scholar 

  23. Keeling J, Teng J, Herrera GA. AL-amyloidosis and light chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest. 2004;84:1322–38.

    Article  PubMed  CAS  Google Scholar 

  24. Westermark P, Benson MD, Buxbaum JN. Amyloid: toward terminology clarification. Amyloid. 2005;12:1–4.

    Article  PubMed  CAS  Google Scholar 

  25. Falk RH, Skinner M. The systemic amyloidoses: an overview. Adv Intern Med. 2000;45:107–37.

    PubMed  CAS  Google Scholar 

  26. Herrera GA. Renal manifestations of plasma cell dyscrasias: an appraisal from the patient’s bedside to the research laboratory. Ann Diagn Pathol. 2000;4:174–200.

    Article  PubMed  CAS  Google Scholar 

  27. Dember LM. Light chains, casts, sheets and fibrils: monoclonal immunoglobulin diseases and immunotactoid/fibrillaryglomerulopathy. Clin J Am Soc Nephrol. 2006;1:1320–1.

    Article  PubMed  Google Scholar 

  28. Ganeval D, Noël LH, Preud’homme JL, et al. Light-chain deposition disease: its relation with AL-type amyloidosis. Kidney Int. 1984;26(1):1.

    Article  PubMed  CAS  Google Scholar 

  29. Korbet SM, Schwartz MM, Lewis EJ. Immunotactoidglomerulopathy (fibrillary glomerulonephritis). Clin J Am Soc Nephrol. 2006;1:1351–6.

    Article  PubMed  Google Scholar 

  30. Alpers CE, Kowalewska J. Fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol. 2008;19:34–7.

    Article  PubMed  Google Scholar 

  31. Dimopoulos MA, Panayiotidis P, Moulopoulos LA. Waldenström’s macroglobulinemia: clinical features, complications, and management. J Clin Oncol. 2000;18:214–26.

    PubMed  CAS  Google Scholar 

  32. Gerz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and waldenström’s macroglobulinemia. J Clin Oncol. 1993;11:914.

    Google Scholar 

  33. Veltman GA, van Veen S, Kluin-Nelemans JC. Renal disease in waldenström’s macroglobulinaemia. Nephrol Dial Transplant. 1997;12:1256.

    Article  PubMed  CAS  Google Scholar 

  34. Penfield JG. Multiple myeloma in end-stage renal disease. Semin Dial. 2006;19:329–34.

    Article  PubMed  Google Scholar 

  35. Levi M, Ellis MA, Berl T. Control of renal hemodynamics and glomerular filtration rate in chronic hypercalcemia. Role of prostaglandins, renin-angiotensin system and calcium. J Clin Invest. 1983;71(6):1624.

    Article  PubMed  CAS  Google Scholar 

  36. Dimopoulos MA, Kastritis E, Rosinol L, et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22:1485–93.

    Article  PubMed  CAS  Google Scholar 

  37. Dimopoulos M, Kyle R, Fermand JP. Guidelines for standard investigative workup: report of the international myeloma workshop consensus panel 3. Blood. Prepublished online February 2, 2011:1–17.

    Google Scholar 

  38. Rajkumar VS, Kyle AK. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2005;80:1371–82.

    Article  PubMed  Google Scholar 

  39. Katzmann JA, Clark RJ, Abraham RS. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437–44.

    PubMed  CAS  Google Scholar 

  40. Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol. 2008;141:413–22.

    Article  PubMed  CAS  Google Scholar 

  41. Johnson WJ, Kyle RA, Pineda AA. Treatment of renal failure associated with multiple myeloma. Arch Intern Med. 1990;150:863–9.

    Article  PubMed  CAS  Google Scholar 

  42. Zuchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1998;33:1175–80.

    Article  Google Scholar 

  43. Clark WF, Steart AK, Rock GA. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005;132:777–84.

    Google Scholar 

  44. Hutchinson CA, Bradwell AR, Cook M. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009;4:745–54.

    Article  Google Scholar 

  45. Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone as initial therapy for multiple myeloma: a comparative analysis of 411 patients. Blood. 2010;115:1343.

    Article  PubMed  CAS  Google Scholar 

  46. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated multiple myeloma. Br J Haematol. 2005;129:776.

    Article  PubMed  CAS  Google Scholar 

  47. Knudsen LM, Nielsen B, Gimsing P. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol. 2005;75:22–33.

    Article  Google Scholar 

  48. Lee CK, Zangari M, Barlogie B. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 2004;33:823–8.

    Article  PubMed  CAS  Google Scholar 

  49. Palumbo A, Bertola A, Musto P, et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer. 2005;104:1428.

    Article  PubMed  CAS  Google Scholar 

  50. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906.

    Article  PubMed  CAS  Google Scholar 

  51. Mehta J, Cavo M, Singhal M. How I treat elderly patients with myeloma. Blood. 2010;116:2215–23.

    Article  PubMed  CAS  Google Scholar 

  52. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood. 2009;114:5436–43.

    Article  PubMed  CAS  Google Scholar 

  53. Comenzo RL. How I treat amyloidosis. Blood. 2009;114:3147–57.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Medicine, University of Washington, 325 Ninth Avenue, Seattle, WA, 98104, USA

    Fionnuala C. Cormack M.D.

  2. Department of Hematology, VA – Puget Sound Health Care System, University of Washington School of Medicine, 1660 S. Columbian Way, Seattle, WA, 98180, USA

    Robert E. Richard M.D.

Authors
  1. Fionnuala C. Cormack M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert E. Richard M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fionnuala C. Cormack M.D. .

Editor information

Editors and Affiliations

  1. Chicago College of Medicine, Nephrology, University of Illinois, Wisconsin Avenue 3543, Berwyn, 60402, Illinois, USA

    Edgar V. Lerma

  2. , Division of Nephrology, University of Virginia Health System, Box 800133, Charlottesville, 22908, Virginia, USA

    Mitchell Rosner

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Cormack, F.C., Richard, R.E. (2013). Multiple Myeloma and the Kidney. In: Lerma, E., Rosner, M. (eds) Clinical Decisions in Nephrology, Hypertension and Kidney Transplantation. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4454-1_50

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-4454-1_50

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-4453-4

  • Online ISBN: 978-1-4614-4454-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation